華昊中天醫藥-B(02563.HK)公佈年度業績 毛利率大幅提高 將進一步加強研發投入
格隆匯6月30日丨華昊中天醫藥-B(02563.HK)公吿,截至2024年12月31日止年度,集團收入為人民幣71.9百萬元,同比增加7.9%。該變動乃主要由於公司的產品(優替德隆注射液)市場滲透提高導致銷售收入增長。公司的虧損由2023年的人民幣189.6百萬元縮減45.8百萬元至2024年的人民幣143.8百萬元。
集團的毛利由截至2023年12月31日止年度的人民幣46.8百萬元增加30.5%至截至2024年12月31日止年度的人民幣61.1百萬元。集團的毛利率於截至2024年12月31日止年度為85.0%,而截至2023年12月31日止年度則為70.3%。毛利及毛利率的增加得益於產品市場滲透提高導致銷售收入增長、產品生產工藝優化所帶來的銷售成本降低。
截至本報吿期末,公司擁有一種已商業化產品及19項研發管線。公司的核心產品優替德隆注射液於2021年獲得國家藥監局批准上市,適應症為與卡培他濱聯合治療既往接受過至少一種蒽環類或紫杉類藥物化療方案的復發或轉移性乳腺癌。這結束了中國近二十年來缺乏自主研發的國產一類化療創新藥的局面。截至本報吿期末,優替德隆注射液是唯一通過合成生物學技術開發並獲批上市的化療藥物,也是2010年起全球獲批准的唯一具有新型分子結構的微管抑制劑類腫瘤藥物。
公司表示,公司將進一步加強研發投入,圍繞產品管線,通過自主研發及外部合作,提升產品的商業價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.